Search results
Showing 1 to 15 of 73 results for cerebral palsy
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
Cerebral palsy in under 25s: assessment and management (NG62)
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.
This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS191Show all sections
This quality standard covers diagnosing, assessing and managing cerebral palsy in children and young people under 25. It describes high-quality care in priority areas for improvement.
View quality statements for QS162Show all sections
Sections for QS162
- Quality statements
- Quality statement 1: Follow-up for children with major risk factors for cerebral palsy
- Quality statement 2: Referral for children with delayed motor milestones
- Quality statement 3: Information for parents and carers of children and young people with cerebral palsy
- Quality statement 4: Personal folders for children and young people with cerebral palsy
- About this quality standard
All NICE products on cerebral palsy. Includes any guidance, advice and quality standards.
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
A Progressive Resistance Strength Training Group for Children with Cerebral Palsy
delivered by Children's Therapy Services for children and young people with cerebral palsy. The audit standards were constructed...
Cerebral Palsy Integrated Pathway - an interprofessional approach
standardised programme to prevent hip dislocations in children with Cerebral Palsy (CP) - Cerebral Palsy Integrated Pathway...
Selective dorsal rhizotomy for spasticity in cerebral palsy (IPG373)
Evidence-based recommendations on selective dorsal rhizotomy for spasticity in cerebral palsy. This involves cutting nerves in the lower spine that are responsible for muscle rigidity.
View recommendations for IPG373Show all sections
Sections for IPG373
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
Question Managing communication difficulties in children with cerebral palsy:- What is the clinical and cost effectiveness of...
NG62/1 Question Optimising nutritional status in children with cerebral palsy:- What is the clinical and cost effectiveness of early...